

Zhuoming Liu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1532080/zhuoming-liu-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

3,475
citations

27
h-index

57
g-index

57
ext. papers

5,543
ext. citations

18.9
avg, IF

5.76
L-index

#	Paper	IF	Citations
54	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.. <i>MBio</i> , 2022 , e0344221	7.8	3
53	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <i>Science</i> , 2022 , 375, eabm8143	33.3	23
52	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.. <i>MBio</i> , 2022 , e0337721	7.8	2
51	Germinal centre-driven maturation of B cell response to mRNA vaccination.. <i>Nature</i> , 2022 ,	50.4	15
50	Defining the risk of SARS-CoV-2 variants on immune protection.. <i>Nature</i> , 2022 ,	50.4	7
49	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , 2022 , 14, eabn1252	17.5	3
48	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry 2021 ,		7
47	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021 , 37, 109881	10.6	6
46	JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 2021 ,		8
45	Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization 2021 ,		44
44	A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants 2021 ,		9
43	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021 , 29, 477-488.e4	23.4	423
42	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains 2021 ,		2
41	Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 2021 ,		44
40	A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope 2021 ,		6
39	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021 , 184, 2332-2347.e16	56.3	316
38	Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody 2021 ,		14

37	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape 2021 ,		12
36	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021 , 596, 103-108	50.4	91
35	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-10	4.4	8
34	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021 , 29, 44-57.e9	23.4	525
33	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 2021 ,		34
32	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021 , 597, 103-108	50.4	94
31	Multivalent designed proteins protect against SARS-CoV-2 variants of concern 2021 ,		4
30	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021 , 597, 97-102	50.4	118
29	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021 , 36, 109364	10.6	42
28	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 1572-1585	8	80
27	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021 , 54, 2399-2416.e6	32.3	30
26	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021 , 54, 2159-2166.e6	32.3	27
25	Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. <i>MBio</i> , 2021 , 12, e0239521	7.8	5
24	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. <i>Science Immunology</i> , 2020 , 5,	28	531
23	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020 , 28, 475-485.e5	23.4	252
22	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020 , 3606354	1	12
21	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 2020 ,		12
20	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 2020 ,		10

19	Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition 2020 ,		32
18	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 32105-32113 ^{11.5}		96
17	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 20803-20813	11.5	87
16	SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response. <i>Frontiers in Immunology</i> , 2020 , 11, 618402	8.4	8
15	Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to <i>Clostridium difficile</i> toxin A entry into cells. <i>Nature Microbiology</i> , 2019 , 4, 1760-1769	26.6	32
14	Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. <i>Current Pharmaceutical Design</i> , 2019 , 25, 4251-4263	3.3	4
13	Herpes Simplex Virus 1 Recruits CD98 Heavy Chain and β Integrin to the Nuclear Membrane for Viral De-Envelopment. <i>Journal of Virology</i> , 2015 , 89, 7799-812	6.6	27
12	Role of Host Cell p32 in Herpes Simplex Virus 1 De-Envelopment during Viral Nuclear Egress. <i>Journal of Virology</i> , 2015 , 89, 8982-98	6.6	44
11	Role of herpes simplex virus 1 immediate early protein ICP22 in viral nuclear egress. <i>Journal of Virology</i> , 2014 , 88, 7445-54	6.6	42
10	Herpes simplex virus 1 protein kinase Us3 phosphorylates viral dUTPase and regulates its catalytic activity in infected cells. <i>Journal of Virology</i> , 2014 , 88, 655-66	6.6	28
9	Role of the nuclease activities encoded by herpes simplex virus 1 UL12 in viral replication and neurovirulence. <i>Journal of Virology</i> , 2014 , 88, 2359-64	6.6	9
8	Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34, and Us3 and regulates viral nuclear egress. <i>Journal of Virology</i> , 2014 , 88, 4657-67	6.6	49
7	Herpes simplex virus 1 protein kinase Us3 and major tegument protein UL47 reciprocally regulate their subcellular localization in infected cells. <i>Journal of Virology</i> , 2011 , 85, 9599-613	6.6	34
6	Landscape Analysis of Escape Variants Identifies SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum Antibody Neutralization. <i>SSRN Electronic Journal</i> ,	1	41
5	TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes		35
4	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion		6
3	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants		1
2	Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination		1

1 Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

5